CORE 4- Small Animal Core

CORE 4-小动物核心

• 批准号: 10625691
• 负责人: Eric P Skaar
• 金额: $ 18.26万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-03-03 至 2028-02-29
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10625691
• 关键词: Animals; Antibodies; Antigens; Board Certification; Clostridium difficile; Development; Goals; Infection; Laboratories; Lead; Modeling; Mus; Pathologist; Pathology; Program Development; Proteins; Resource Sharing; Testing; Training; Treatment Efficacy; Vaccines; Veterinary Anatomy; digital pathology; efficacy testing; experience; human disease; human model; in vivo Model; molecular pathology; mouse model; novel vaccines; prevent; programs; small molecule; therapeutic evaluation; vaccine development

SUMMARY-SMALL ANIMAL CORE A critical component of our vaccine development program is efficacy testing of candidate antigens in murine models of C. difficile infection. The Small Animal Core of our program will achieve this goal and identify lead antigens for the development of novel vaccines to prevent against CDI. The Small Animal Core will be led by Dr. Eric Skaar. The Skaar laboratory has significant experience in the murine model of C. difficile infection and has also developed a new live C. difficile vaccine model in mice as described in Project 2. In addition, the Skaar laboratory has experience testing the therapeutic efficacy of both small molecules and antibodies in murine models. This experience will be used to guide the creation of a Small Animal Core to test the efficacy of lead antigens developed by this program. The Small Animal Core will benefit from the expertise of the Translational Pathology Shared Resource (TPSR) which includes access to a board-certified veterinary pathologist with experience in in vivo modeling of human disease, including molecular pathology, toxicopathologic assessment, and digital pathology as well as advanced training in veterinary anatomic pathology and murine models. The Small Animal Core will receive optimized candidate antigens from Scientific Core 2. These proteins will be tested for efficacy in appropriate murine models of CDI. Candidate antigens will be tested alone or in combination. Combined, the efforts of the Small Animal Core will result in the identification of lead antigens for the development of novel vaccines that protect against infections caused by C. difficile.

小动物核心概述 我们的疫苗开发计划的一个关键组成部分是候选抗原在小鼠中的效力测试。 C.模型艰难感染我们计划的小动物核心将实现这一目标，并确定铅 用于开发预防CDI的新型疫苗的抗原。小动物中心将由博士领导。 埃里克·斯卡尔。Skaar实验室在C.艰难感染， 还开发了一种新的live C。小鼠艰难梭菌疫苗模型，如项目2中所述。此外，Skaar 一个实验室有测试小分子和抗体在小鼠中的治疗效果的经验。 模型该经验将用于指导小动物核心的创建，以测试铅的有效性 这个项目开发的抗原。小动物核心将受益于翻译的专业知识， 病理学共享资源（TPSR），包括获得委员会认证的兽医病理学家， 在人类疾病的体内建模方面的经验，包括分子病理学，毒理病理学评估， 和数字病理学以及兽医解剖病理学和小鼠模型的高级培训。的 Small Animal Core将接收来自Scientific Core 2的优化候选抗原。这些蛋白质将被测试 在适当的CDI鼠模型中的疗效。候选抗原将单独或联合检测。 结合起来，小动物中心的努力将导致鉴定用于开发的先导抗原。 新的疫苗可以预防C.很难